

SUPPLEMENTARY MATERIAL

doi: 10.4081/monaldi.2024.3004

A bibliometric analysis of cystic fibrosis transmembrane conductance regulators

Bashar Araiqtat,¹ Sebawe Syaj,¹ Aseel Al-Khatib,¹ Nour Al-Bzour,¹
Narmine Hussein,¹ Sarah Aqel,² Jamil Ahmad³

¹Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan;
²Medical Research Center, Hamad Medical Corporation, Doha, Qatar; ³Department of
Urology, Hamad Medical Corporation, Doha, Qatar.

Correspondence: Bashar Araiqtat, Faculty of Medicine, Jordan University of Science and
Technology,
Irbid 22110, Jordan.
Tel.: +962799086534.
Fax: +962799086534.
E-mail: saqel1@hamad.qa

Key words: cystic fibrosis, CFTR protein, CFTR modulators, bibliometric analysis, Scopus.

Supplementary Table 1. Top-contributing institutions according to the number of publications, and citations.

Institutions – According to no. of publications	Country	Publications	Citations
University of Alabama at Birmingham, Birmingham, United States	United States	120	10,993
Vertex Pharmaceuticals, Boston, United States	United States	89	11,300
University of Washington, Seattle, United States	United States	73	8,161
Hospital For Sick Children, Toronto, On, Canada	Canada	49	9,689
Imperial College London, London, United Kingdom	United Kingdom	42	7,056
Cystic Fibrosis Foundation, Bethesda, United States	United States	39	1,823
Vertex Pharmaceuticals (Europe) Limited, London, United Kingdom	United Kingdom	33	3,746
Charité – Universitätsmedizin Berlin, Berlin, Germany	Germany	22	3,611
St. Vincent's University Hospital, Dublin, Ireland	Ireland	21	6,249
Case Western Reserve University School of Medicine, Cleveland, United States	United States	19	4,203
Harvard Medical School, Boston, United States	United States	18	1,268
Université Paris Descartes, Paris, France	France	14	387
Queens University Belfast, Belfast, United Kingdom	United Kingdom	13	4,500
University Medical Center, Utrecht, Netherlands	Netherlands	13	3,435
Northwestern University, Chicago, United States	United States	13	1,754
McGill University, Montréal, Canada	Canada	10	3,082
Medical University Of South Carolina, Charleston, United States	United States	10	1,505
National Jewish Health, Denver, CO, United States	United States	9	591
Galapagos Nv, Mechelen, Belgium	Belgium	9	205
Queensland Children's Medical Research Institute, Brisbane, Australia	Australia	7	3,522
Justus-Liebig-University Giessen, Giessen, Germany	Germany	7	153
Institutions – According to no. of citations	Country	Publications	Citations
Vertex Pharmaceuticals, Boston, United States	United States	89	11,300
University of Alabama at Birmingham, Birmingham, United States	United States	120	10,993
Hospital For Sick Children, Toronto, Canada	Canada	49	9,689
University of Washington, Seattle, United States	United States	73	8,161
Imperial College London, London, United Kingdom	United Kingdom	42	7,056
St. Vincent's University Hospital, Dublin, Ireland	Ireland	21	6,249
Queens University Belfast, Belfast, United Kingdom	United Kingdom	13	4,500

Case Western Reserve University School of Medicine, Cleveland, United States	United States	19	4,203
Vertex Pharmaceuticals (Europe) Limited, London, United Kingdom	United Kingdom	33	3,746
Charité – Universitätsmedizin Berlin, Berlin, Germany	Germany	22	3,611
Queensland Children's Medical Research Institute, Brisbane, Australia	Australia	7	3,522
University Medical Center, Utrecht, Netherlands	Netherlands	13	3,435
McGill University, Montréal, Canada	Canada	10	3,082
Charles University, Prague, Czech Republic	Czech Republic	3	2,763
Stanford University School of Medicine, Stanford, Ca, United States	United States	6	2,645
Prince Charles Hospital, Brisbane, Australia	Australia	3	2,156
Cystic Fibrosis Foundation, Bethesda, United States	United States	39	1,823
Northwestern University, Chicago, United States	United States	13	1,754
Centre D'investigation Clinique-Hôpital Necker, Paris, France	France	1	1,676
Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland	Ireland	1	1,676
University of Munich, Munich, Germany	Germany	1	1,676

Supplementary Table 2. Top cited authors.

Author	Documents	Citations	Author	Documents	Citations
Rowe S.M.	83	8351	Clevers H.	3	1142
Mckone E.F.	34	6318	Colombo C.	11	1141
Ramsey B.W.	29	5691	Bronsveld I.	7	1132
Konstan M.W.	25	4351	Lukacs G.L.	12	1072
Elborn J.S.	29	4170	Mccoy K.	5	1067
Tullis E.	15	4136	Nieuwenhuis E.E.S.	2	1060
Ratjen F.	40	3931	Jain R.	21	1038
Waltz D.	18	3844	Middleton P.G.	8	1026
Wainwright C.E.	17	3640	Cipolli M.	3	1020
Davies J.C.	47	3112	Higgins M.	15	997
Marigowda G.	13	3099	Mayer-Hamblett N.	22	995
Taylor-Cousar J.L.	39	2872	Vermeulen F.	6	953
Mall M.A.	36	2786	Veit G.	10	940
Simard C.	9	2709	Gonska T.	22	935
Munck A.	12	2592	Donaldson S.H.	20	930
Dřevínek P.	2	2577	Bear C.E.	29	924
Sermet-Gaudelus I.	34	2518	Lands L.C.	2	914
Yen K.	3	2333	Vx17-445-102 Study Group	1	901
Bell S.C.	13	2303	Lekstrom-Himes J.	3	889
De Boeck K.	23	2278	Sagel S.D.	21	889
Rodriguez S.	4	2127	Li H.	8	875
Griese M.	6	2087	Ingenito E.P.	2	873
Van Der Ent C.K.	29	2031	Mckee C.	2	873
Mccolley S.A.	24	1992	Sorscher E.J.	16	869
Mcelvaney N.G.	14	1991	Clancy J.P.	36	794
Davies J.	6	1963	Borowitz D.	9	786
Tian S.	17	1919	Avramescu R.G.	6	779
Moskowitz S.M.	10	1861	Bijvelds M.J.C.	5	779
Dong Q.	3	1827	Scholte B.J.	4	776
Xuan F.	7	1763	Wang L.T.	5	772
Boyle M.P.	7	1743	Daines C.	3	762
Beekman J.M.	25	1711	Sheppard D.N.	20	757
Huang X.	4	1691	Stoltz D.A.	12	724

Moss R.	1	1676	Amaral M.D.	22	713
Ordoñez C.	1	1676	Kruisselbrink E.	12	711
Flume P.A.	20	1611	Ordoñez C.L.	3	700
Mckee C.M.	4	1596	Brandsma A.M.	1	689
Van Goor F.	11	1573	De Jong N.W.M.	1	689
De Winter-De Groot K.M.	11	1430	Middendorp S.	1	689
De Jonge H.R.	16	1429	Van Den Brink S.	1	689
Savage J.	3	1368	Wiegerinck C.L.	1	689
Heltshe S.L.	27	1351	Hadjiliadis D.	9	680
Janssens H.M.	10	1351	Berkers G.	12	660
Dekkers J.F.	5	1283	Spencer H.	2	654
Nair N.	2	1253			
Polineni D.	4	1249			
Sawicki G.S.	30	1229			
Cutting G.R.	13	1180			


Supplementary Table 3. Top 10 most cited articles.

First author	Year	Title	Source title	Cited by
Ramsey B.W.	2011	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation	New England Journal of Medicine	1,676
Wainwright C.E.	2015	Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR	New England Journal of Medicine	1,008
Middleton P.G.	2019	Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele	New England Journal of Medicine	901
Dekkers J.F.	2013	A functional CFTR assay using primary cystic fibrosis intestinal organoids	Nature Medicine	689
Dedrick R.M.	2019	Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus	Nature Medicine	648
Heijerman H.G.M.	2019	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial	The Lancet	603
Cutting G.R.	2015	Cystic fibrosis genetics: From molecular understanding to clinical application	Nature Reviews Genetics	584
Taylor-Cousar J.L.	2017	Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del	New England Journal of Medicine	521
Mogayzel Jr. P.J.	2013	Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health	American Journal of Respiratory and Critical Care Medicine	476
Bell S.C., Mall M.A.	2020	The future of cystic fibrosis care: a global perspective	The Lancet Respiratory Medicine	454

Supplementary Table 4. Year trends and the number of citations per year.

Year	Overall	Cited by	
	(N = 2,317)	Mean (SD)	Median [Min, Max]
2010-2015	471	37.97 (112.38)	8.00 [0, 1676]
2016-2020	945	26.11 (59.84)	12.0 [0, 901]
2021-2023	901	6.350 (12.94)	2.00 [0, 196]

SD, standard deviation.



Supplementary Figure 1. Annual trends mean citation and publication counts.